GEMCITABINE, GEMCITABINE, INFLIXIMAB, DURVALUMAB, MYCOPHENOLATE MOFETIL, CISPLATIN
Phase 3 small_molecule active
Quick answer
GEMCITABINE, GEMCITABINE, INFLIXIMAB, DURVALUMAB, MYCOPHENOLATE MOFETIL, CISPLATIN for Patients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladder is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Patients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladder
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active